Status:
WITHDRAWN
Evaluation of the Clinical Performances of a Point of Care Analyzer Enabling Pre-transfusion ABOD Group Ultimate Verification at the Patient Bedside
Lead Sponsor:
Francis Corazza
Conditions:
Blood Transfusion Complication
Eligibility:
All Genders
Up to 80 years
Phase:
NA
Brief Summary
ABO-incompatible red blood cell transfusions still represent an important hazard in transfusion medicine. Therefore, some countries have introduced a systematic bedside ABO agglutination test checking...
Detailed Description
ABO-incompatible red blood cell transfusions still represent an important hazard in transfusion medicine. Therefore, some countries have introduced a systematic bedside ABO agglutination test checking...
Eligibility Criteria
Inclusion
- For the device evaluation inside the laboratory : every patient for whom a blood group is ordered to the blood transfusion laboratory.
- For the device bedside evaluation : each patient from the hematology unit (one day clinic) requiring a transfusion.
Exclusion
- Emergency circumstances requiring an urgent transfusion
- Patient older than 80 years old
- Patients with venous access
Key Trial Info
Start Date :
April 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2025
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04344613
Start Date
April 10 2020
End Date
October 1 2025
Last Update
October 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Brugmann
Brussels, Belgium, 1020